©The Author(s) 2022.
World J Gastroenterol. Sep 14, 2022; 28(34): 5058-5075
Published online Sep 14, 2022. doi: 10.3748/wjg.v28.i34.5058
Published online Sep 14, 2022. doi: 10.3748/wjg.v28.i34.5058
Table 1 Baseline patient and disease characteristics
| Characteristics | N | n (%) or mean ± SD | |
| Age | 94 | 42.5 (15.3) | |
| Gender | Male | 94 | 56 (59.6) |
| BMI (kg/m2) | 91 | 25.4 (4.5) | |
| Race | American Indian/Alaska Native | 94 | 1 (1.1) |
| Asian | 5 (5.3) | ||
| White | 88 (93.6) | ||
| Employment status | Disability | 2 (2.1) | |
| Employed (fulltime, part time < 35 h/week) | 63 (67.0) | ||
| Homemaker | 3 (3.2) | ||
| Retired | 12 (12.8) | ||
| Student | 6 (6.4) | ||
| Temporary leave of absence | 1 (1.1) | ||
| Unemployed | 6 (6.4) | ||
| Unknown | 1 (1.1) | ||
| Tobacco use | Current smoker | 94 | 2 (2.1) |
| Former smoker | 34 (36.2) | ||
| Never smoked | 55 (58.5) | ||
| Unknown | 3 (3.2) | ||
| Alcohol use | Non-drinker | 94 | 20 (21.3) |
| Ex-drinker | 5 (5.3) | ||
| Light (less than 2 drinks per day) | 61 (64.9) | ||
| Moderate (2-4 drinks per day) | 5 (5.3) | ||
| Unknown | 3 (3.2) | ||
| Age at UC diagnosis (yr) | 98 | 34.5 (15.3) | |
| Disease duration (yr) | 98 | 7.9 (8.0) | |
| Family history of UC | No | 98 | 59 (60.2) |
| Yes | 20 (20.4) | ||
| Unknown | 19 (19.4) | ||
| Montreal classification of extent of UC | E2 | 97 | 55 (56.7) |
| (prior 3 mo) | E3 | 42 (43.3) | |
| Mayo Endoscopic Subscore | 1 | 90 | 1 (1.1) |
| (prior 3 mo) | 2 | 66 (73.3) | |
| 3 | 23 (25.6) | ||
| Endoscopy (prior 6 mo) | Yes | 98 | 91 (92.9) |
| UC-related ED visit (prior 6 mo) | Yes | 98 | 13 (13.3) |
| UC-related hospitalization (prior 6 mo) | Yes | 98 | 12 (12.2) |
| Previous biologic use | Yes | 44 | 5 (11.4) |
| Medication use: | Corticosteroids | 98 | 63 (64.3) |
| Since UC diagnosis to prior 6 mo | Imuran (azathioprine) | 37 (37.8) | |
| 6-MP | 8 (8.2) | ||
| 5-ASA | 83 (84.7) | ||
| Methotrexate | 5 (5.1) | ||
| Cyclosporine | 1 (1.0) | ||
| Medication use: | Corticosteroids | 98 | 61 (62.2) |
| Since prior 6 mo to current | Imuran (azathioprine) | 39 (39.8) | |
| 6-MP | 5 (5.1) | ||
| 5-ASA | 67 (68.4) | ||
| Methotrexate | 8 (8.2) | ||
| Cyclosporine | 0 (0.0) |
- Citation: Bessissow T, Nguyen GC, Tarabain O, Peyrin-Biroulet L, Foucault N, McHugh K, Ruel J. Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study. World J Gastroenterol 2022; 28(34): 5058-5075
- URL: https://www.wjgnet.com/1007-9327/full/v28/i34/5058.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i34.5058